Почему SPO Гемабанка может стать одной из самых необычных историй на Мосбирже?

Gemabank is the only public company in the Russian personal stem cell storage market. The company combines a stable dividend business with high margins and development in the biotech sector. With preparations underway for an IPO, it's especially interesting to understand why the company is pursuing a new offering, what challenges it could solve, and how Gemabank envisions future business growth. Live, we'll discuss: 👉 How is Gemabank's business structured and how does it generate revenue? 👉 Why did the company decide to conduct an IPO now? 👉 What could the funds be used for? 👉 What's happening in the Russian stem cell storage market? 👉 What growth drivers and risks should investors consider? Guests of #smartlabonline will be: • Ivan Potapov, Director of PJSC MMCB, Gemabank • Dmitry Krasotkin, IR Director of PJSC Artgen Biotech 00:00 — Introduction 00:52 — Financial Indicators and Plans 01:44 — Revenue and Operations 02:42 — Cost of Services 04:13 — Storage Volume and Growth 06:53 — Service Relevance 10:03 — Biomaterial Application 10:59 — Treatment Mechanics 12:54 — Sales Funnel 14:55 — Collaboration with Clinics 15:35 — Bioinsurance Service Coverage 16:29 — Impact of Birth Rate on Demand 17:10 — Penetration Increasing Strategies 17:42 — Additional Share Placement 18:59 — Prospects for Placement in Market Conditions 21:23 — Goals Placement 22:07 — Disease Examples and Development Stages 24:22 — Development Timing and Stages 25:45 — Investment Mechanisms 26:51 — Loans and Balance Sheet Assets 29:57 — Capitalization Assessment and Financial Assets 30:56 — Loan Structure and Business Model 32:42 — Cash Flow and Assets 33:35 — Bioinsurance Market 35:02 — Financial Performance and Dividends 36:21 — Revenue Forecast 40:06 — Capital Expenditures 41:33 — Debt and Credit Rating 43:33 — Tax Regimes 44:31 — Accounts Payable and Loans 45:19 — Loan and Deposit Policy 46:13 — Artgen Shares on the Balance Sheet 47:34 — Placement Organizers 48:05 — Analytical Review and Share Placement 48:57 — Risks of Gene Therapy Research 51:55 — Investment Prospects and Goals 53:20 — Conclusion